CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy

Current Opinion in Investigational Drugs

Volumn 4, Issue 6, 2003, Pages 686-690

  Jahrsdörfer, Bernd ^a   Weiner, George J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Cancer immunotherapy; CpG ODN; Monoclonal antibody; Oligodeoxynucleotides

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CPG 7909; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE A; CPG OLIGODEOXYNUCLEOTIDE B; DNA VACCINE; IMMUNOTOXIN LMB2; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELLULAR IMMUNITY; CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; FEVER; HUMAN; HYPERGLYCEMIA; HYPOTENSION; IMMUNOSTIMULATION; NAUSEA; NONHUMAN; PROTEIN MOTIF; REVIEW; RIGOR; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES;

EID: 17044447484     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci (1893) 105:487-511.
2. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E, Rothenfusser S, Endres S, Hartmann G: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol (2002) 32(11):3235-3245. A combination of peritumoral injections of CpG ODN with tumor-distant application of antigen-pulsed DC plus CpG ODN enabled the immune system to reject large, standard therapy-resistant, solid tumors in a CD8 T-cell-dependent manner.
3. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S, Hartmann G: Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol (2002) 169(7):3892-3899. Peritumoral CpG DNA monotherapy removed tolerance toward growing tumors by eliciting a strong and long-term memory-based CD8 T-cell response.
4. Zwaveling S, Ferreira Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, Van Der Burg SH, Melief CJ: Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol (2002) 169(1):350-358. Vaccinations with the HPV16-derived 35-amino-acid-long peptide E7, containing both a CTL epitope and a Th epitope, admixed with the dendritic cell-activating adjuvant CpG DNA resulted in the eradication of large, established HPV16-expressing tumors.
5. Stern BV, Boehm BO, Tary-Lehmann M: Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ-dependent CD4 cell immunity. J Immunol (2002) 168(12):6099-6105. Immunization with the tumor-specific peptide H11.1, using an immunostimulatory CpG oligonucleotide as adjuvant, led to a 25-fold increase in clonal, Th1-polarized CD4 cells compared with immunization without adjuvant. CpG DNA functioned as a stronger Th1 adjuvant that CFA and, unlike CFA, elicited protective, IFNγ-dependent immunity.
6. Pisetsky DS, Reich CF III: Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol (1999) 58(12):1981-1988.
7. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
8. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ: (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167(9):4878-4886.
9. Cowdery JS, Chace JH, Yi AK, Krieg AM: Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 156(12):4570-4575.
10. Lipford GB, Sparwasser T, Bauer M, Zimmermann S, Koch ES, Heeg K, Wagner H: Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. Eur J Immunol (1997) 27(12):3420-3426.
11. Krieg AM: CpG DNA: A pathogenic factor in systemic lupus erythematosus? J Clin Immunol (1995) 15(6):284-292.
12. Chace JH, Hooker NA, Mildenstein KL, Krieg AM, Cowdery JS: Bacterial DNA-induced NK cell IFN-γ production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol (1997) 84(2):185-193.
13. Sparwasser T, Miethke T, Lipford G, Erdmann A, Hacker H, Heeg K, Wagner H: Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor-α-mediated shock. Eur J Immunol (1997) 27(7):1671-1679.
14. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol (1998) 161(6):3042-3049.
15. Liu HM, Newbrough SE, Bhatia SK, Dahle CE, Krieg AM, Weiner GJ: Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood (1998) 92(10):3730-3736.
16. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol (1998) 28(6):2045-2054.
17. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K: CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. Eur J Immunol (1997) 27(9):2340-2344.
18. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2002) 20:709-760. A comprehensive review of the biology and function of immunostimulatory CpG DNA.
19. Ashkar AA, Rosenthal KL: Toll-like receptor 9, CpG DNA and innate immunity. Curr Mol Med (2002) 2(6):545-556.
20. McCluskie MJ, Weeratha RD: Novel adjuvant systems. Curr Drug Targets Infect Disord (2001) 1(3):263-271.
21. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3(2):196-200.
22. Kerkmann M, Rothenfusser S, Hornung V, Towarowski A, Wagner M, Sarris A, Giese T, Endres S, Hartmann G: Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol (2003) 170(9):4465-4474.
23. Blazar BR, Krieg AM, Taylor PA: Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood (2001) 98(4):1217-1225.
24. Sfondrini L, Besusso D, Zoia MT, Rodolfo M, Invernizzi AM, Taniguchi M, Nakayama T, Colombo MP, Menard S, Balsari A: Absence of the CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. J Immunol (2002) 169(1):151-158.
25. Carpentier AF, Xie J, Mokhtari J, Delattre JY: Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 6(6):2469-2473.
26. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling GJ: NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol (2001) 167(9):5247-5253.
27. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkins lymphoma. Blood (1997) 90(6):2188-2195.
28. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol (1998) 16(8):2659-2671.
29. Warren TL, Dahle CE, Weiner GJ: CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma (2000) 1(1):57-61.
30. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89(8):2994-2998. A single dose of CpG DNA was as effective as multiple doses of IL-2 at inhibiting tumor growth when combined with antitumor monoclonal antibody.
31. Van Ojik HH, Bevaart L, Dahle CE, Bakker A, Jansen MJ, Van Vugt MJ, Van De Winkel JG, Weiner GJ: CpG-A and B ODN enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res (2003) in press.
32. Decker T, Hipp S, Kreitman RJ, Pastan I, Peschel C, Licht T: Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides. Blood (2002) 99(4):1320-1326.
33. Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukocyte Biol (2001) 69(1):81-88. CpG ODN led to increasing expression of molecules involved in costimulation, antigen presentation and targets for antibody-based therapy.
34. Schirmbeck R, Melber K, Kuhrober A, Janowicz ZA, Reimann J: Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo. J Immunol (1994) 152(3):1110-1119.
35. Baldridge JR, Ward JR: Effective adjuvants for the induction of antigen-specific delayed type hypersensitivity. Vaccine (1997) 15(4):395-401.
36. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long term results of a clinical trial. Blood (1997) 89(9):3129-3135.
37. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R: Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann NY Acad Sci (1993) 690:385-387.
38. Chen HY, Wu SL, Yeh MY, Chen CF, Mikami Y, Wu JS: Antimetastatic activity induced by Clostridium butyricum and characterization of effector cells. Anticancer Res (1993) 13(1):107-111.
39. Johnston D, Bystryn JC: Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine. J Natl Cancer Inst (1991) 83(17):1240-1245.
40. Mastrangelo MJ, Maguire HC Jr, Sato T, Nathan FE, Berd D: Active specific immunization in the treatment of patients with melanoma. Semin Oncol (1996) 23(6):773-781.
41. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, Marciani D: Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine (1994) 12(14):1275-1280.
42. Davila E, Celis E: Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol (2000) 165(1):539-547.
43. 3) and Th-cell proliferative responses which were significantly higher than with E7 alone. CTL responses were induced only by E7 + CpG ODN.
44. 2a than CFA did, suggesting an enhanced Th1 response. Mice immunized with CpG ODN as an adjuvant were protected from tumor challenge to a degree similar to that seen in mice immunized with CFA.
45. Krieg AM, Matson S, Fisher E: Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev (1996) 6(2):133-139.
46. Cooper CL, Davis HL, Krieg AM, Morris ML, Elfer SM, Heathcote J, Cameron DW: Improved hepatitis B vaccine response with CpG ODN-7909 adjuvant. Can J Infect Dis Suppl B (2001) 12:Abs 120.
47. Vabulas RM, Pircher H, Lipford GB, Hacker H, Wagner H: CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses. J Immunol (2000) 164(5):2372-2378.
48. Shirota H, Sano K, Hirasawa N, Terui T, Ohuchi K, Hattori T, Tamura G: B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12. J Immunol (2002) 169(2):787-794.
49. Hartmann G, Weiner GJ, Krieg AM: CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA (1999) 96(16):9305-9310.
50. Warren TL, Bhatia SK, Acosta AM, Dahle CE, Ratliff TL, Krieg AM, Weiner GJ: APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol (2000) 165(11):6244-6251. CpG ODN enhanced the development of a cellular immune response by stimulating APCs such as DCs, to produce IL-12 and other soluble factors.
51. Brunner C, Seiderer J, Schlamp A, Bidlingmaier M, Eigler A, Haimerl W, Lehr HA, Krieg AM, Hartman G, Endres S: Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol (2001) 165(11):6278-6286.
52. Egeter O, Mocikat R, Ghoreschi K, Dieckmann A, Rocken M: Eradication of disseminated lymphomas with CpG-DNA activated T helper type 1 cells from nontransgenic mice. Cancer Res (2000) 60(6):1515-1520.
53. Yasuda K, Ogawa Y, Kishimoto M, Takagi T, Hashida M, Takakura Y: Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochem Biophys Res Commun (2002) 293(1):344-348.
54. Haupt K, Roggendorf M, Mann K: The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (2002) 227(4):227-237.
55. Bronte V: Genetic vaccination for the active immunotherapy of cancer. Curr Gene Ther (2001) 1(1):53-100.
56. Cohen AD, Boyer JD, Weiner DB: Modulating the immune response to genetic immunization. FASEB J (1998) 12(15):1611-1626.
57. Spooner RA, Deonarian MP, Epenetos AA: DNA vaccination for cancer treatment. Gene Ther (1995) 2(3):173-180.
58. Ulmer JB, Donnelly JJ, Liu MA: Toward the development of DNA vaccines. Curr Opin Biotechnol (1996) 7(6):653-658.
59. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, Silverman GJ, Lotz M, Carson DA, Raz E: Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science (1996) 273(5273):352-354.
60. Shoda LK, Kegerreis KA, Suarez CE, Mwangi W, Knowles DP, Brown WC: Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-α, and NO production by bovine macrophages. J Leukocyte Biol (2001) 70(1):103-112.
61. Brazolot-Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL: CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA (1998) 95(26):15553-15558.
62. Rudginsky S, Siders W, Ingram L, Marshall J, Scheule R, Kaplan J: Antitumor activity of cationic lipid complexed with immunostimulatory DNA. Mol Ther (2001) 4(4):347-355.